西氏医药服务 2026年季度报告

Securities registered pursuant to Section 12(b) of the Act: Title of each classCommon Stock, par value $0.25 per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☑ As of April20, 2026, there were 70,647,595 shares of the registrant’s common stock outstanding. Page PART I. FINANCIAL INFORMATION PART II. OTHER INFORMATION PART I. FINANCIAL INFORMATION ITEM 1.FINANCIAL STATEMENTSCONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)West Pharmaceutical Services, Inc. and Subsidiaries(in millions, except per share data) West Pharmaceutical Services, Inc. and Subsidiaries(in millions) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 1:Basis of Presentation Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been preparedin accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting andU.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derivedfrom audited financial statements but does not include all disclosures required by U.S. GAAP. Certain information and footnotedisclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary fora fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The West Vantage:Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segmentto "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition Held for Sale Assets:In December 2025, the Company entered into a definitive agreement to sell all manufacturing and supply rightsfor the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie for approximately $112.5million, subject toworking capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close inmid-2026. In relation to this agreement, the carrying values of certain assets were classified as held for sale in our consolidatedbalance sheets as of March31, 2026 and December31, 2025 and recorded within other current assets. There were no liabilities Note 2:New Accounting Standards Recently Adopted Standards In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09,Income Taxes: Improvements to Income Tax Disclosures, that seeks to enhance income tax disclosures to provide information to betterassess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax ratereconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over aspecified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and Standards Issued Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—ExpenseDisaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, that seeks to improve the disclosuresabout a public business entity’s expenses and address requests from investors for more detailed information about the types ofexpenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonlypresented expense captions. The amendments require that at each interim and annual reporting period an entity: (1